ABOUT US
Prazer Therapeutics was established with the core mission to help patients suffering from intractable diseases by using logical and innovative approaches to drug design.
We aim to accomplish this mission through our new and innovative drug development platforms, including rational molecular drug design technology and next-generation protein degradation technology.
Our hope is to challenge and overcome the current unmet medical needs through our platform technologies. We are willing to collaborate with all partners to achieve our goal: a healthy society without disease.
Making undruggable targets druggable, making incurable diseases curable.
Our hope is to challenge and overcome the current unmet medical needs through our platform technologies. We are willing to collaborate with all partners to achieve our goal: a healthy society without disease.
Making undruggable targets druggable, making incurable diseases curable.
Directors
- CEOKyung-Soo Inn
- Prazer Therapeutics, CEO
- KYUNG HEE University Associate Professor, Department of Pharmaceutical Science, College of Pharmacy
- University of Southern California Postdoctoral Research Fellow, Keck School of Medicine, Department of Molecular Microbiology and Immunology
- Harvard Medical School Postdoctoral Research Fellow, New England Primate Research Center (NEPRC), Department of Microbiology and Genetics
- Aprogen Inc. Senior Research Scientist, (Team Leader, Therapeutic Antibody Development Team)
- Seoul National University Ph.D., Department of Microbiology and Immunology, College of Medicine
- KAIST (Korea Advanced Institute of Science and Technology) B.S., Department of Biological Sciences
Kyung-Soo InnCEO
- CSO (Chief Scientific Officer)Nam-Jung Kim
- Prazer Therapeutics, CSO
- Kyung Hee University Associate Professor, Department of Life and Nanopharmaceutical Sciences
- Scripps Research Institute Postdoctoral Research Fellow
- Seoul National University Ph.D., Division of Synthetic Organic and Medicinal Chemistry, College of Pharmacy
- Seoul National University B.S., College of Pharmacy
Nam-Jung KimCSO (Chief Scientific Officer)
- CTO (Chief Technology Officer)Jong-Kil Lee
- Prazer Therapeutics, CTO
- Kyung Hee University Assistant Professor, College of Pharmacy
- Kyungpook National University Postdoctoral Research Fellow, Department of Physiology, School of Medicine
- Kyungpook National University Ph.D., Department of Laboratory Animal Medicine, Colleage of Veterinary Medicine
- Kyungpook National University B.S., Colleage of Veterinary Medicine
Jong-Kil LeeCTO (Chief Technology Officer)
- CFOJung-Jin Ahn
- Prazer Therapeutics, CFO
- Blue Point Partners Founding Partner
- SK Telecom China Holdings Business Director
- WEBZEN INC. Team Leader, Global Business Department
- KAIST (Korea Advanced Institute of Science and Technology) B.S., Business Administration
Jung-Jin AhnCFO
Scientific Advisors
- Seoul National UniversityNam-Hyuk Cho
Nam-Hyuk ChoSeoul National University
- Seoul National UniversityBum-Joon Kim
Bum-Joon KimSeoul National University
- Dankook UniversityYoung-Taek Han
Young-Taek HanDankook University
Partners
- Kyung Hee University
Kyung Hee University
- KITE Entrepreneurship Foundation
KITE Entrepreneurship Foundation
- Company K partners
Company K partners
- Smilegate Investment
Smilegate Investment
- Kiwoom Investment
Kiwoom Investment
- KTB Network
KTB Network
-
PRAZER THERAPEUTICS
Headquarter / R&D centerTel. +82-2-6217-1020 Fax. +82-2-6217-1018 E-mail. master@prazertx.com
#1103, D, dept. 26, Beobwon-ro 9-gil, Songpa-gu, Seoul, Repurblic of KoreaCOPYRIGHT(C) WWW.PRAZERTX.COM. ALL RIGHT RESERVED.
-
COPYRIGHT(C) WWW.PRAZERTX.COM. ALL RIGHT RESERVED.
